DynamiCure

DynamiCure is a private, pre-revenue biotechnology company founded in 2018 and headquartered in Waltham, Massachusetts. The company's core focus is 'immuno-normalization,' an approach aimed at restoring immune system balance to treat cancer and autoimmune disorders. Its most advanced asset, DC-6001, consists of two anti-CD93 monoclonal antibodies, with one currently in a Phase 1 clinical trial for advanced cancers. The company is led by scientific founder Dr. Lieping Chen, a world-renowned immunologist who pioneered the PD-1/PD-L1 pathway research.

Immuno-normalization platform focused on discovering therapeutic antibodies that restore immune system balance by targeting novel pathways like CD93 to normalize diseased microenvironments (e.g., tumor vasculature).

Operates in the highly competitive immuno-oncology space dominated by large pharma with approved checkpoint inhibitors. Competitors include other companies developing vascular normalization therapies (e.g., anti-VEGF, angiopoietin-2 inhibitors) and potentially other undisclosed CD93-targeting programs. Differentiation hinges on first-in-class epitope-specific antibodies and the broader immuno-normalization platform.